- Home
- KALU vs CDNA Comparison
KALU vs CDNA Comparison
Compare KALU & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- CDNA
- Stock Information
- Founded
- KALU 1946
- CDNA 1998
- Country
- KALU United States
- CDNA United States
- Employees
- KALU N/A
- CDNA N/A
- Industry
- KALU Metal Fabrications
- CDNA Medical Specialities
- Sector
- KALU Industrials
- CDNA Health Care
- Exchange
- KALU Nasdaq
- CDNA Nasdaq
- Market Cap
- KALU 1.2B
- CDNA 1.0B
- IPO Year
- KALU 1991
- CDNA 2014
- Fundamental
- Price
- KALU $84.17
- CDNA $19.49
- Analyst Decision
- KALU Buy
- CDNA Buy
- Analyst Count
- KALU 3
- CDNA 6
- Target Price
- KALU $69.00
- CDNA $30.33
- AVG Volume (30 Days)
- KALU 131.7K
- CDNA 982.3K
- Earning Date
- KALU 07-23-2025
- CDNA 07-30-2025
- Dividend Yield
- KALU 3.65%
- CDNA N/A
- EPS Growth
- KALU 0.39
- CDNA N/A
- EPS
- KALU 3.06
- CDNA 1.07
- Revenue
- KALU $3,063,900,000.00
- CDNA $346,421,000.00
- Revenue This Year
- KALU $11.04
- CDNA $13.31
- Revenue Next Year
- KALU $7.33
- CDNA $15.46
- P/E Ratio
- KALU $27.50
- CDNA $17.54
- Revenue Growth
- KALU 1.56
- CDNA 25.92
- 52 Week Low
- KALU $46.81
- CDNA $14.09
- 52 Week High
- KALU $100.07
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- KALU 73.73
- CDNA 57.30
- Support Level
- KALU $79.44
- CDNA $18.64
- Resistance Level
- KALU $81.90
- CDNA $19.84
- Average True Range (ATR)
- KALU 2.32
- CDNA 0.83
- MACD
- KALU 0.34
- CDNA -0.05
- Stochastic Oscillator
- KALU 96.02
- CDNA 69.64
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.